Trials / Terminated
TerminatedNCT05391633
Maternal Voice and Quantitative EEG (qEEG)
Effect of Recorded Maternal Voice on Quantitative EEG (qEEG) as a Marker for Developmental Risk in the Preterm Newborn
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of New Mexico · Academic / Other
- Sex
- All
- Age
- 28 Weeks – 33 Weeks
- Healthy volunteers
- Not accepted
Summary
A short-term randomized, blinded placebo-controlled trial, in premature infants in the neonatal intensive care unit (NICU) at 33-35 weeks post-conceptional age, of recorded maternal voice on quantitative EEG (spectral power density) as a marker of development.
Detailed description
This will be a randomized placebo-controlled clinical trial. Infants consented to participate will be randomized into the intervention arm or non-intervention arm by sealed unmarked envelope. All consented participants will have an initial EEG of 60-90 minutes duration, performed at 32 5/7 - 32 6/7 weeks (and after 72 hours of life). Starting at 33 0/7 weeks corrected gestational age (regardless of birth gestation), eligible subjects will proceed with randomized intervention or placebo for a 2-week (14 day) intervention period. All infants will receive a 2nd EEG of 30-60 minutes duration, performed between 35 0/7 - 35 6/7 weeks corrected gestational age, following completion of either the intervention or non-intervention arm (with the goal of the 2nd EEG occurring within 48 hours of infants having completed the intervention vs. non-intervention arm). EEG technician and all persons reviewing, pruning and analyzing data from the qEEG will be blinded to whether the infant was in the intervention or the non-intervention arm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Recorded Maternal Voice | 60-minute looped recording of maternal voice, played once daily for 14 total days. |
| BEHAVIORAL | Placebo Recording | 60-minute blank recording played once daily for 14 total days. |
Timeline
- Start date
- 2022-02-15
- Primary completion
- 2024-06-12
- Completion
- 2024-06-12
- First posted
- 2022-05-26
- Last updated
- 2025-09-15
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05391633. Inclusion in this directory is not an endorsement.